Market Overview

UPDATE: KeyBanc Upgrades BioMed Realty Trust to Buy on Lease-Up and Accretive Acquisitions

Related BMR
UPDATE: Stifel Downgrades BioMed Realty Trust On Valuation
High-Yield REITs Show Strength As U.S. 10-Year Treasury Falls Below 2%
The Best Stocks To Buy This Week (Seeking Alpha)

KeyBanc upgraded BioMed Realty Trust (NYSE: BMR) from Hold to Buy and announced a $24.00 price target.

KeyBanc commented, "Following strong execution on the leasing front, a pipeline of accretive investment activity and a reloading of the balance sheet, we are upgrading shares of BioMed Realty Trust (BMR-NYSE) to BUY from HOLD, and establishing a $24 per share price target. Supported by significant strength in the life science sector, the Company made impressive progress on the leasing front over the last five quarters, driving portfolio occupancy up by more than 500 bps to a healthy 89.2%; we suspect the recent robust pace of FDA drug approvals and private capital investment will translate into additional occupancy upside over the next year."

BioMed Realty Trust closed at $20.97 on Wednesday.

Latest Ratings for BMR

Feb 2015Stifel NicolausDowngradesBuyHold
Nov 2014Stifel NicolausMaintainsBuy
Oct 2014Mizuho SecuritiesInitiates Coverage onBuy

View More Analyst Ratings for BMR
View the Latest Analyst Ratings

Posted-In: KeyBancAnalyst Color Upgrades Analyst Ratings


Related Articles (BMR)

Around the Web, We're Loving...